Biogen (NASDAQ: BIIB), one of the world's leading biopharma companies, generates billions of dollars in sales every quarter. But I'm increasingly concerned that headwinds facing its top-selling multiple sclerosis drugs will weigh down sales growth in the future. Can Biogen overcome this risk to its revenue?
The MS drug market is worth $20 billion annually, and Biogen is the Goliath in the market, with a 38% market share.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com